Wang, Qiaoyu;
Tao, Hua;
Fei, Zhimin;
Wang, Shuo;
Hu, Xin;
Li, Ling;
Liu, Dong;
Tao, Xia;
Xie, Jian;
Guo, Ruichen;
Zhao, Chengson;
Wang, Rui.
We have updated the guideline for preventing and managing perioperative infection in China, given the global issues with antimicrobial resistance and the need to optimize antimicrobial usage and improve hospital infection control levels. We conducted a comprehensive evaluation of the evidence for prevent...
Zeng, Mei;
Xia, Jun;
Zong, Zhiyong;
Shi, Yi;
Ni, Yuxing;
Hu, Fupin;
Chen, Yijian;
Zhuo, Chao;
Hu, Bijie;
Lv, Xiaoju;
Li, Jiabin;
Liu, Zhengyin;
Zhang, Jing;
Yang, Wenjie;
Yang, Fan;
Yang, Qiwen;
Zhou, Hua;
Li, Xin;
Wang, Jianhua;
Li, Yimin;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Commercial arrangement
There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Commercial arrangement
There is a simple discount patient access scheme for upadacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. N...
The Feldenkrais method is presumably preferred by social groups who generally strive to use non-drug and non-surgical interventions for preventing and treating diseases. Since chronic pain is more common in advanced age, older people are likely to be more interested in this method. This health technology...
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT‑ON (Sense4care) for remote monitoring of Parkinson’s disease....
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Commercial arrangement
There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...
